We have studied the effect of glucocorticoids administered in vivo on the activity and synthesis of the cyclooxygenase enzyme (COX) in mice treated with or without concurrent intravenous administration of LPS. Mouse peritoneal macrophages from LPS-treated animals showed a two to three fold increase in COX activity determined by the production of PGE2 and PGI2 after stimulation of the cells with exogenous arachidonate. Dexamethasone injected simultaneously with LPS, 12 h before killing of the animal and removal of the macrophages, completely blocked the LPS-induced increase COX activity in peritoneal macrophages. The regulation observed in COX activity by LPS and dexamethasone are due primarily to changes in COX mass as determined by immunoprecipitation of I35Slmethionine endogenously labeled enzyme. In contrast, the COX present in the nonadherent cells and in renal medullary microsomes obtained from the same animals, showed no significant changes between treatments. These results indicate that LPS in vivo stimulates COX synthesis in the peritoneal macrophages but not in the kidney. The effect of dexamethasone to inhibit COX synthesis is selective to the LPS-induced enzyme.
Introduction
Anti-inflammatory steroids together with nonsteroidal anti-inflammatory drugs are widely employed for the treatment of acute and chronic inflammatory diseases. While the mechanism of action of nonsteroidal agents has been shown to result from blockade of prostanoid production by inhibition of cyclooxygenase (COX)' (1) , the mechanism(s) of anti-inflammatory steroids is still unknown. Glucocorticoids modulate the synthesis of a number of proteins, among these a 35-40 kD polypeptide (lipocortin) which was thought to inhibit phospholipase A2 (2) , thereby reducing the formation of proinflammatory eicosanoid products. Also, human recombinant lipocortin 1 has been shown to have anti-inflammatory properties in the rat paw edema test (3) . However, recent studies have raised serious doubts about glucocorticoid-induced lipocortin formation (4) , and whether lipocortin inhibits phospholipase (5) or rather acts as a phospholipid binding protein (6) . Moore and Holt (7), and Wood and co-workers (8) have re- ported data that suggest that glucocorticoids inhibit COX activity. Also, it has been shown that dexamethasone (DEX) suppress cyclooxygenase messenger RNA levels in cultured vascular cells (9) . We have recently demonstrated that DEX inhibits in vitro COX activity by suppressing the de novo synthesis of COX enzyme in human dermal fibroblasts (10) , cultured monocytes (1 Oa) , and macrophages (unpublished results). However, this effect of DEX must be validated in vivo in order to fully unravel the potential therapeutic value of this observation and to avoid interpretation of mechanism fully dependent on tissue culture conditions. Although several in vivo studies showed that eicosanoid metabolism is not affected by steroid administration (12-18), we report the effect of glucocorticoids administered in vivo on the activity of COX and 5-lipoxygenase enzymes in normal condition and in a systemic model of inflammation, e.g., endotoxin LPS administered in vivo.
Methods
Preparation ofanimals. Male Balb C mice (8-9 wk old) were used and divided into four treatment groups. Group 1 received saline, group 2 received endotoxin, group 3 received endotoxin with dexamethasone, and group 4 received dexamethasone only. Endotoxin (LPS from Salmonella typhimurium Re C30/C21; Ribi ImmunoChem Research, Inc., Hamilton, MT) was given as a single intravenous injection (tail vein) of 50 ,gg in 200 ,l of sterile saline or in combination with dexamethasone (5 mg/kg). After treatment, all mice were returned to their cages with free access to food and water until they were used. At specified times after treatment, mice were sacrificed in a CO2 chamber and the peritoneal cells were obtained by lavaging the peritoneal cavity with cold PBS. Cell counts were performed using a hemocytometer and differentials performed on cell preparations made with a cytospin (Shandon Southern Instruments Inc., Pittsburgh, PA) stained with Giemsa.
Macrophage isolation. Peritoneal cells (1-2 X 106 cells) were allowed to adhere to 24-well tissue culture plates for 2 h (37°C, 5% CO2) in DMEM, 10% fetal calf serum, and 100 ,g penicillin/streptomycin.
The nonadherent cells were removed by washing three times in calcium and magnesium-free PBS. The cell preparation was more than greater than 90% macrophages as judged by morphological criteria under the light microscope.
COX activity. Cellular COX activity in the macrophages was measured by incubating the intact cells in DMEM with 30MiM arachidonic acid for 10 min. Aliquots of the incubation mixture were assayed for PGE2, 6-keto-PGFIa, and TxB2 formation by specific radioimmunoassays (19, 20) . The cells were washed with PBS and solubilized in 0.62 N NaOH for protein determination by the Coomassie brilliant blue reagent (21 4 h. Cells were washed, collected, and solubilized in solubilization buffer Tris-HCl 50 mM; EDTA 10 nM; NP40 1%, diethyldithiocarbamic acid (DCC) I mM; pH = 8.0. After sonication and centrifugation (100,000 g, 15 min), aliquots of the supernatant containing the solubilized COX were immunoprecipitated with specific COX antibody (10) after preclearance with normal rabbit serum. Immunoprecipitation was completed by using protein-A-Sepharose (Sigma Chemical Co., St. Louis, MO). After three washes with 50 mM Tris-HCI, 5 mM EDTA, 150 mM NaCl, 0.5% Triton X-100, 0.1% SDS, 10 U/ml Trasylol, pH = 8.0, two further washes with the same buffer without detergents were made and the pellets processed for SDS/PAGE as described (10) . The proteins in the gel were fixed, soaked in Amplify (Amersham Corp.), dried, and exposed to XAR-5 film (Kodak Laboratory and Specialty Chemicals, Rochester, NY) at -70°C. COX band is determined by its migration on SDS/PAGE 70 Kd protein and by cold competition experiments with 5 ug of purified COX (Cayman Chemical Co., Ann Arbor, MI). Relative intensities of COX band were determined by laser densitometric scanning of the films under conditions in which band intensity was proportional to radioactivity and exposure time.
Kidney microsomal COX. Microsomes were prepared as previously described (22). Briefly, medullary portions from kidneys obtained from the different treatment groups were homogenized in phosphate buffer and the 10,000 g supernatant was isolated. Microsomes were then obtained from a 100,000 g spin, and the microsomal pellet resuspended in phosphate buffer. Microsomes were then incubated with 30 MM arachidonic acid in the presence of 1 MM epinephrine for 10 min at 37°C. The reaction was stopped by cooling the tubes at 0°C before testing for the formation of PGE2-Induction ofleukotrienesformation by zymosan. We used a modification ofthe method ofDoherty et al. (23, 1 1) that is known to produce an acute model of inflammation with synthesis of peptidoleukotrienes without cellular influx for at least 2 h. Mice that have been injected intravenously with LPS, DEX, or both for 12 h received intraperitoneal injections of 1 mg of zymosan in 1 ml of sterile PBS. At 1 or 2 h after the injections, mice were killed using CO2 and the peritoneum was lavaged with 2 ml of ice-cold saline. The cell content of peritoneal lavage fluids as well as differential analysis was made as previously described. The lavage fluid was centrifuged 10,000 g for 5 min and the supernatants were frozen at -20°C until assays.
Some animals were treated with indomethacin, 1 mg/kg s.c. 30 min before the zymosan injections. LTB4 and LTC4 were assayed by specific immunoassays already described (24).
Statistics. Statistical analysis was performed by a one-way analysis of variance. If this indicated significance, comparison between groups were analyzed by a Student's t test. Significance was accepted at P < 0.05.
Results
Effects ofLPS and DEX in vivo. Intravenous injections of LPS (50 ,ug per mouse), dexamethasone (5 mg/kg), or both produced no change in the total number of intraperitoneal leukocytes, mainly macrophages, obtained 12 h after administration macrophages, we found that LPS produced a two-to threefold increase in the activity ofthe COX enzyme when measured as the production of PGE2 or 6-keto-PGFIa ( Fig. 1 A and B) .
COX activity was slightly diminished in the DEX group (P < 0.05) when assessed as PGE2 formation (Fig. 1 A) . However, when DEX was co-injected with LPS, a complete inhibition of the LPS enhancement of COX activity was observed ( Fig. 1 ( (Fig. 2) showed that LPS given in vivo produced a threefold increase in the de novo synthesis of COX compared with control cells. Dexamethasone given in vivo resulted in a 40% reduction in the radioactivity associated with COX, but its major effect was a 80% inhibition of the LPS-induced COX (Fig. 2) . The inhibitory effect of DEX on LPS-induced COX synthesis was dose dependent (Fig. 3) Effect of LPS and DEX on 5-lipoxygenase activity. After the in vivo injections of LPS, DEX, or both, mice were subjected to an acute inflammatory stimulus by the injection of 1 mg/ml zymosan i.p. During the first 2 h postzymosan administration, there was substantial endogenous metabolism of arachidonic acid in the peritoneum via both the 5-lipoxygenase and the cyclooxygenase pathways (10, 1 1), without marked changes in number or types of intraperitoneal leukocytes. Analysis of the peritoneal lavage fluids (Table II) showed that the major component, 6-keto-PGFI,, was stimulated by LPS and blocked by DEX similar to the changes observed in the macrophages that were analyzed for COX activity in vitro. Leukotriene B4 was detected in all the peritoneal fluid tested; however, the animals which were injected with LPS or the combination of LPS and DEX showed a 50% reduction in the LTB4 production after 1 h of zymosan injections compared with the controls or the animals that received DEX alone. LTC4 production was unchanged after 1 h, but its production was also modestly decreased in the LPS or LPS + DEX group (10) or by LPS in the human blood monocyte (1Oa), effects that in both instances are completely blocked by DEX (10) . We also investigated the effect on 5-lipoxygenase by DEX in the peritoneal macrophage in vivo. Intraperitoneal zymosan injections produced a rapid activation of the 5-lipoxygenase enzyme as observed by the production of LTB4 and LTC4. DEX treated animals demonstrated no changes in their ability to produce leukotrienes, indicating that upon activation, 5- nine showed a 40±12% (n = 4) reduction in de novo COX synthesis during the incubation period. One possible explanation is that DEX exerts some of its effect on PG formation via increased stability of the existing constitutive enzyme with no net change in total cellular COX activity.
Given the observation that DEX may inhibit differentially the basal and LPS stimulated COX, we hypothesize the possibility of functionally distinct COX enzymes. Clearly, those putative enzyme pools may arise as different gene products, possibly through the expression of different COX genes under regulatory control by glucocorticoids. This hypothesis is currently under investigation.
The in vivo glucocorticoid effect on eicosanoid metabolism we report here differs from previous studies that propose the mechanism of glucocorticoid inhibition of arachidonic acid release is due to the inhibition of phospholipase A2 activity by the lipocortins (27) . However, recent reports dispute this mechanism of inhibition because (a) lipocortins do not inhibt phospholipase A2 activity in vitro (5, 6); and (b) dexamethasone does not induce lipocortin mRNA or mass (4, 28) in systems where glucocorticoids are known to inhibit eicosanoid formation (28) .
Our recent data and others in vitro provide an alternative hypothesis for the regulation of the arachidonic acid metabolism that involves the direct induction and inhibition of the COX. IL-1 (29), phorbol myristate acetate (PMA) (10), PDGF (30) , and LPS (submitted) have all been shown to induce COX synthesis in vitro with a subsequent increase in arachidonic metabolite release. In 1982, Hawkey (31) reported that prednisolone inhibits COX activity in vitro in human rectal mucosa, and more recently it has been demonstrated that steroids suppress COX mRNA levels and prostanoid synthesis in cultured vascular cells (9) . In our laboratory, we also demonstrated that DEX is able to inhibit the synthesis of COX in vitro in human dermal fibroblasts (10) 
